|1.||Sevillano, Sara: 2 articles (04/2004 - 04/2003)|
|2.||de Dios, Isabel: 2 articles (04/2004 - 04/2003)|
|3.||Manso, Manuel A: 2 articles (04/2003 - 08/2002)|
|4.||Pestka, James J: 1 article (12/2012)|
|5.||Flannery, Brenna M: 1 article (12/2012)|
|6.||Clark, Erica S: 1 article (12/2012)|
|7.||Jiao, R S: 1 article (01/2011)|
|8.||Zhang, G W: 1 article (01/2011)|
|9.||Gao, H R: 1 article (01/2011)|
|10.||Yang, C X: 1 article (01/2011)|
02/01/2004 - "In a recent report of a study in a rat model of obstructive acute pancreatitis, however, it was suggested that a potent CCK1 antagonist, L364,718, had proved harmful. "
02/01/2004 - "This article reviews the findings obtained with CCK antagonists in several experimental models of pancreatitis and assesses the recent findings with L364,718 in that light."
08/01/2002 - "Similar increases in the intracellular enzyme content were found at earlier stages of pancreatitis in all PDO rats treated or not treated with L364,718. "
08/01/2002 - "L364,718 (0.1 mg/kg/12 hr) was administered from 30 min before inducing acute pancreatitis (AP) by pancreatic duct obstruction (PDO) for 48 hr. The results obtained at different AP stages in PDO rats treated and not treated with the CCK antagonist were compared. "
09/01/1998 - "L 364,718 administered for seven days after inducing pancreatitis significantly reduced WGA binding, untreated rats showed a normal zymogen granule membrane. "
|2.||Pancreatic Neoplasms (Pancreatic Cancer)
06/01/1990 - "Effects of a high-fat diet and L364,718 on growth of human pancreas cancer."
11/01/1994 - "In this study, we examined the ability of MK-329 to modulate DDP sensitivity in vivo using MIA-PaCa2 pancreatic cancer xenografts growing subcutaneously in athymic nude mice. "
01/01/1992 - "A pilot clinical trial of the cholecystokinin receptor antagonist MK-329 in patients with advanced pancreatic cancer."
01/01/1992 - "While a role for MK-329 in the management of patients with advanced pancreatic cancer cannot be supported by the results of this trial, additional studies of this agent in patients with known CCK receptor-positive tumors, at escalated doses, and possibly in conjunction with other growth antagonists, appear warranted."
01/01/1994 - "Enhancement of the cytotoxicity of cisplatin by the cholecystokinin antagonist MK-329 in a human pancreatic cancer cell line."
11/01/1994 - "The combination of DDP and MK-329 resulted in enhanced tumor growth delay compared to DDP or MK-329 treated mice. "
11/01/1994 - "Both DDP and MK-329 alone caused a reduction in the rate of tumor growth. "
11/01/1994 - "Twenty-four hours after tumor inoculation, mice received either DDP intraperitoneally, MK-329 subcutaneously, both DDP and MK-329 or drug vehicles alone. "
07/15/1994 - "Infusion of MK329 during the initiation period of carcinogenesis did not change tumor incidence or yield, suggesting that endogenous CCK does not influence tumor induction during the initiation period in the hamster."
06/01/1990 - "Since both tumor and pancreas growth are inhibited by the specific CCK-antagonist, L364,718, it is possible that endogenous CCK promotes the growth."
01/01/1990 - "Administered alone, MK-329 did not affect food intake, indicating that its reversal of (+ -fenfluramine-induced anorexia was not secondary to an intrinsic hyperphagic effect. "
03/17/1994 - "The present study compared the patterns of c-fos protein-like immunoreactivity (FLI) induced in rat brain by CCK and the indirect 5HT agonist dexfenfluramine (DFEN), as well as the ability for devazepide, a CCK-A receptor antagonist, to antagonize both anorexia and FLI induced by these agents. "
12/01/2012 - "Food intake experiments using the NPY2 receptor antagonist BIIE0246 and the CCK1A receptor antagonist devazepide, individually, suggested that PYY mediated DON-induced anorexia but CCK did not. "
03/01/1999 - "Devazepide, a CCK(A) receptor antagonist, appeared to interact with tropisetron in the anorectic responses to IMB, blunting the usual remediation of IMB anorexia by tropisetron. "
03/17/1994 - "Cholecystokinin- and dexfenfluramine-induced anorexia compared using devazepide and c-fos expression in the rat brain."
06/01/1993 - "Moreover, devazepide did not reduce the elevated pain limen caused by milk or fat infusions. "
01/01/1992 - "The results of the study failed to demonstrate any impact of MK-329 on tumor progression, pain, or nutrition. "
03/01/1989 - "Both CCK (4-16 micrograms/kg) and MK-329 (0.1-8.0 mg/kg) had no significant effect on thresholds for pain when given alone, whereas morphine (2-16 mg/kg) induced dose-dependent analgesia. "
01/01/2011 - "L-364,718 potentiates electroacupuncture analgesia through cck-a receptor of pain-related neurons in the nucleus parafascicularis."
12/01/1990 - "These data suggest that devazepide may have therapeutic utility as an adjuvant to morphine analgesia allowing lower dose of the opiate to be used to relieve pain and reducing the risk of opiate-induced respiratory depression."
|1.||Cholecystokinin Receptors (Cholecystokinin Receptor)
|3.||Somatostatin (Somatotropin Release-Inhibiting Factor)
|4.||FOY 305 (camostat)
|7.||Cholecystokinin A Receptor
|8.||Morphine (MS Contin)
|2.||Heterologous Transplantation (Xenotransplantation)